Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on May 19, 2023 12:08pm
130 Views
Post# 35456632

RE:RE:RE:RE:RE:What's next and when

RE:RE:RE:RE:RE:What's next and whenLike me, you and everyone else, Paul is not perfect and he is also very expensive. But THTX is a tiny company and it is unlikely we would be able to attract anyone of his pedigree to replace him. While we really cannot  afford him right now, that could change pretty quickly. If TH-1902 ends up being successful in phase 1b and moves forward into phase II, THTX will need a partner and Paul gives us a reputable and experienced person to guide any potential partnership discussions. Paul is a option on TH-1902. If it fails then I suspect he would leave of his own accord for greener pastures. If it succeeds, he will likley stick around and guide the company to greener pastures. His participating in such conferences may be part of his plan to prepare for leaving in case that becomes necessary. I have no problem with that. But I hope TH-1902 works and there is good reason for him to stick around as TH-1902 provides a lot of possible routes to substantial future growth.
LouisW wrote: @SPCEO, what do you think regarding Paul actively participating conferences talking about investment and innovation? 


<< Previous
Bullboard Posts
Next >>